2. Search Result
Search Result
Results for "

metastatic colorectal cancer

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Peptides

4

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W181530
    NCT02

    		CDK Cancer
    NCT02 is a cyclin K degrader. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC) .
    NCT02
  • HY-A0061
    Trifluridine
    1 Publications Verification

    Trifluorothymidine; 5-Trifluorothymidine; TFT

    		 Thymidylate Synthase HSV Nucleoside Antimetabolite/Analog Orthopoxvirus DNA/RNA Synthesis Apoptosis Autophagy Cancer
    Trifluridine (Trifluorothymidine) is an irreversible and orally active thymidylate synthase inhibitor, and thereby suppressing DNA synthesis. Trifluridine is an antiviral molecule used for research of HSV, rhabdovirus and orthopoxvirus infection. Trifluridine induces cell apoptosis and autophagy. Trifluridine is also an anticancer agent used in studies of metastatic colorectal cancer, gastrointestinal tumors .
    Trifluridine
  • HY-127009
    Levoleucovorin

    Levofolinic acid; Levofolene

    		 Endogenous Metabolite Cancer
    Levoleucovorin (Levofolinic acid) is the pharmacologically active levoisomer of racemic leucovorin. Levoleucovorin can be used as a rescue agent after high-dose Methotrexate (HY-14519) therapy, and in combination with fluorouracil for the research of advanced metastatic colorectal cancer .
    Levoleucovorin
  • HY-P99476
    ABP 215

    		VEGFR Cancer
    ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .
    ABP 215
  • HY-P3099
    Uroguanylin (human)

    		Guanylate Cyclase Cancer
    Uroguanylin (human) is a natural ligand for the Guanylyl Cyclase (GCC) receptor expressed in metastatic colorectal cancer tumors. Uroguanylin (human) has anti-tumor actions in an animal model for human colon cancer .
    Uroguanylin (human)
  • HY-113680
    KY1022

    		Apoptosis Ras β-catenin Wnt Cancer
    KY1022 is a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway. KY1022 can inhibit cellular EMT, metastasis and apoptosis. KY1022 can be used for the research of metastatic colorectal cancer .
    KY1022
  • HY-109051C
    Arfolitixorin sulfate

    		Endogenous Metabolite Cancer
    Arfolitixorin sulfate is a potent 5-Fluorouracil (5-FU) moderator. Arfolitixorin sulfate is an immediately active form of Folate, [6R]-5,10-methylenetetrahydrofolate ([6R]-MTHF). Arfolitixorin sulfate is potent for the research of metastatic colorectal cancer .
    Arfolitixorin sulfate
  • HY-P99406
    Petosemtamab

    MCLA 158

    		 EGFR Cancer
    Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
    Petosemtamab
  • HY-155747
    FDW028

    		Autophagy Cancer
    FDW028 a potent and highly selective FUT8 inhibitor. FUT8 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the chaperone-mediated autophagy (CMA) pathway. FDW028 can be used for metastatic colorectal cancer (mCRC) research .
    FDW028
  • HY-P99011
    Cibisatamab

    		CD3 Cancer
    Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .
    Cibisatamab
  • HY-P99215
    Parsatuzumab

    Anti-EGFL7; RG 7414

    		 VEGFR Cancer
    Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
    Parsatuzumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: